Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates

Biological Psychiatry

Volumn 77, Issue 5, 2015, Pages 488-492

  Narendran, Rajesh ^a,b   Jedema, Hank P ^b   Lopresti, Brian J ^a   Mason, Neale Scott ^a   Himes, Michael L ^b   Bradberry, Charles W ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; Nonhuman primates; Positron emission tomography; Self administration; Vesicular monoamine transporter type 2 (VMAT2); 11C (+) dihydrotetrabenazine ( 11C DTBZ)

Indexed keywords

COCAINE; DIHYDROTETRABENAZINE CARBON C 11; DOPAMINE; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; CARBON; DIHYDROTETRABENAZINE; DOPAMINE UPTAKE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG SELF ADMINISTRATION; LONG TERM EXPOSURE; MALE; MOOD DISORDER; NERVE ENDING; NONHUMAN; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; RHESUS MONKEY; AGING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; METABOLISM; SCINTISCANNING;

AGING; ANIMALS; BRAIN; CARBON ISOTOPES; COCAINE; COCAINE-RELATED DISORDERS; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; MACACA MULATTA; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SELF ADMINISTRATION; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84923208253     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.06.012     Document Type: Article

References (28)

1. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, S.J. Gatley, and R. Hitzemann Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects Nature 386 1997 830 833
2. R.T. Malison, K.Y. Mechanic, H. Klummp, R. Baldwin, T.R. Kosten, and J.P. Seibyl Reduced amphetamine-stimulated dopamine release in cocaine addicts as measured by [123I]IBZM SPECT J Nucl Med 40 1999 110P
3. D. Martinez, R. Narendran, R. Foltin, M. Slifstein, D.R. Hwang, and A. Broft Amphetamine-induced dopamine release is markedly blunted in cocaine dependent subjects and predictive of the choice to self administer cocaine Am J Psychiatry 164 2007 622 629
4. D. Martinez, K.M. Carpenter, F. Liu, M. Slifstein, A. Broft, and A.C. Friedman Imaging dopamine transmission in cocaine dependence: Link between neurochemistry and response to treatment Am J Psychiatry 168 2011 634 641
5. K.Y. Little, L. Zhang, T. Desmond, K.A. Frey, G.W. Dalack, and B.J. Cassin Striatal dopaminergic abnormalities in human cocaine users Am J Psychiatry 156 1999 238 245
6. K.Y. Little, D.M. Krolewski, L. Zhang, and B.J. Cassin Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users Am J Psychiatry 160 2003 47 55
7. J.M. Wilson, A.I. Levey, C. Bergeron, K. Kalasinsky, L. Ang, and F. Peretti Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users Ann Neurol 40 1996 428 439
8. J.K. Staley, J.Z. Talbot, B.J. Ciliax, G.W. Miller, A.I. Levey, and M.P. Kung Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims Brain Res 747 1997 219 229
9. R. Narendran, B.J. Lopresti, D. Martinez, N.S. Mason, M. Himes, and M.A. May In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers Am J Psychiatry 169 2012 55 63
10. J.M. Wilson, and S.J. Kish The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat J Neurosci 16 1996 3507 3510
11. D. Boulay, D. Duterte-Boucher, I. Leroux-Nicollet, L. Naudon, and J. Costentin Locomotor sensitization and decrease in [3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine J Pharmacol Exp Ther 278 1996 330 337
12. K. Schwartz, R. Nachman, M. Yossifoff, R. Sapir, A. Weizman, and M. Rehavi Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2 J Neural Transm 114 2007 427 430
13. J.M. Brown, G.R. Hanson, and A.E. Fleckenstein Cocaine-induced increases in vesicular dopamine uptake: Role of dopamine receptors J Pharmacol Exp Ther 298 2001 1150 1153
14. R. Narendran, and D. Martinez Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature Synapse 62 2008 851 869
15. J.N. Porter, A.S. Olsen, K. Gurnsey, B.P. Dugan, H.P. Jedema, and C.W. Bradberry Chronic cocaine self-administration in rhesus monkeys: Impact on associative learning, cognitive control, and working memory J Neurosci 31 2011 4926 4934
16. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration Synapse 62 2008 873 876
17. I. Boileau, P. Rusjan, S. Houle, D. Wilkins, J. Tong, and P. Selby Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28 2008 9850 9856
18. M.R. Kilbourn, E.R. Butch, T. Desmond, P. Sherman, P.E. Harris, and K.A. Frey In vivo [11C]dihydrotetrabenazine binding in rat striatum: Sensitivity to dopamine concentrations Nucl Med Biol 37 2010 3 8
19. R. De La Fuente-Fernandez, S. Furtado, M. Guttman, Y. Furukawa, C.S. Lee, and D.B. Calne VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET Synapse 49 2003 20 28
20. N.I. Bohnen, R.L. Albin, R.A. Koeppe, K.A. Wernette, M.R. Kilbourn, S. Minoshima, and K.A. Frey Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease J Cereb Blood Flow Metab 26 2006 1198 1212
21. D.J. Doudet, P. Rosa-Neto, O.L. Munk, T.J. Ruth, S. Jivan, and P. Cumming Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study Neuroimage 30 2006 26 35
22. H.P. Jedema, P.J. Gianaros, P.J. Greer, D.D. Kerr, S. Liu, and J.D. Higley Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission Mol Psychiatry 15 2010 512 522 446
23. M. Kilbourn, L. Lee, T. Vander Borght, D. Jewett, and K. Frey Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific Eur J Pharmacol 278 1995 249 252
24. C. Tai, A. Chatziioannou, S. Siegel, J. Young, D. Newport, and R.N. Goble Performance evaluation of the microPET P4: A PET system dedicated to animal imaging Phys Med Biol 46 2001 1845 1862
25. 11C]NNC 112 in humans: Validation and reproducibility J Cereb Blood Flow Metab 20 2000 225 243
26. A.A. Lammertsma, and S.P. Hume Simplified reference tissue model for PET receptor studies Neuroimage 4 1996 153 158
27. M. Perez-Reyes, S. Di Guiseppi, G. Ondrusek, A.R. Jeffcoat, and C.E. Cook Free-base cocaine smoking Clin Pharmacol Ther 32 1982 459 465
28. K.Y. Little, E. Ramssen, R. Welchko, V. Volberg, C.J. Roland, and B. Cassin Decreased brain dopamine cell numbers in human cocaine users Psychiatry Res 168 2009 173 180